2018 Guest Speakers

 

 

 

 

 

 

Thursday, November 8th:   8:00 a.m.  –  5:00 p.m.

Friday, November 9th:        8:00 a.m.  –  3:00 p.m.

Embassy Suites by Hilton – Philadelphia Airport
9000 Bartram Avenue, Philadelphia, Pennsylvania  19153  USA
TEL:  +1 – 215 – 365-4500   *   FAX:  +1 – 215 – 365 – 3195

 

gerdingphotoDale Gerding, MD, FACP, FIDSA
Dr. Gerding, MD, FACP, FIDSA, Conference Chair, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA) and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.
Presentation Topic:  “Update On Newer Agents For Clostridium difficile Infections.”

Mark Wilcox, MD, FRCPath
Dr. Wilcox, M.D., FRCPath, Conference Chair, serves as a Consultant Microbiologist, Head & Professor of Medical and Academic Lead of Pathology/Clinical Director of Pathology, at the Leeds Teaching Hospitals (LTHT). Dr. Wilcox is a Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences and is the lead on Clostridium difficile for Public Health England in the UK. Dr. Wilcox serves as the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents. He was the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. He serves as Assistant Editor of the Journal of Antimicrobial Chemotherapy and Member of Council of the British Society of Antimicrobial Chemotherapy. Prof. Wilcox serves as a Member of the Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and an Advisor to the UK Healthcare Commission, the Medicines and Healthcare products Regulatory Agency, the EPIC project on infection control issues, the Health Technology Assessment (HTA) programme on Healthcare Associated Infection and the European Centre for Disease Control. Dr. Wilcox serves as a Member of UK, European and US working groups on Clostridium difficile infection.
Presentation Topic:  “Diagnosing a Clostridium difficile Infection (CDI) – Straightforward and Complicated!”

drpaulfeuerstadt Paul Feuerstadt, MD, FACG
Dr. Feuerstadt, MD, FACG,  is a Native of Long Island, New York.
Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training,
Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, NY for his clinical fellowship training.His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on C.diff. infections. Dr.Feuerstadt is affiliated with St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital and Milford Hospital seeing outpatients in his offices in Hamden and Milford, CT
Presentation Topic:  “C. difficile Infection: Life Cycle, Incidence and Burden.”

Nick VanHise, PharmD, BCPS
Dr. VanHise, PharmD, received a Bachelor of Science from Bradley University in Peoria, IL and his Doctorate of Pharmacy from Union University School of Pharmacy in Jackson, TN.Dr. Van Hise then went on to do an infectious disease residency and become board certified in pharmacoltherapy and infectious disease. Dr. Van Hise has been published in various scientific journals, including the New England Journal of Medicine, Clinical Infectious Diseases, and the Journal of Clinical Neuropharmacology.
Presentation Topic:  “The Preventative Approach to An Urgent
Threat; Clostridium difficile.

Maureen Spencer, RN, M.Ed.
Maureen Spencer, RN, M.Ed. has been board certified in infection control (CIC) for over 30 years and is currently the Director, Clinical Implementation at Accelerate Diagnostics, providing educational and consultative services to the sales and marketing teams in the US. She was previously the Corporate Director, Infection Prevention for Universal Health Services in King of Prussia, PA, Infection Control Manager at New England Baptist Hospital, Director Infection Control Unit at Mass General Hospital and other Boston hospitals in a career that has spanned over 40 years.
Presentation Topic:  “Prevention of Antimicrobial Resistance, Sepsis and Antibiotic Side Effects with Fast Molecular Diagnostics for Bloodstream Infections.

Joe Martin, Executive Director, PHC4
Joe Martin, Executive Director, Pennsylvania Health Care Cost Containment Council (PHC4) Mr. Martin, who joined PHC4 in 1991, was appointed to the Executive Director position on November 5, 2009. In this role, he provides leadership to a professional and technical staff of 28 and is responsible for overseeing all agency operations, including the planning, directing, coordinating and executing of all PHC4 initiatives. He also works with a 25-member Council to set policy and work priorities as well as to plan and implement the future direction for PHC4.
Presentation Topic:  “Higher Costs and Worse Outcomes for Patients Hospitalized with a Clostridium difficile Infection.”

Catia Matos Ferreira, MD, Senior Director, Medical Scientific Affairs
Cátia Matos Ferreira received her PhD in analytical chemistry from The Open University in the field of cancer biologic therapeutic development. She completed her postdoctoral training at the Ontario Institute for Cancer Research, Princess Margaret Cancer Centre, and the University of Toronto, in the departments of medical biophysics in the field of ontological drug development.  Dr. Ferreira previously worked at GlaxoSmithKline
(GSK Vaccines) leading projects related to HPV and influenza vaccine development and implementation.  Dr. Ferreira currently leads the Pfizer global Medical and Scientific Affairs vaccine program directed at the prevention of diseases due to Clostridium difficile.
Presentation Topic:  “C. difficile Prevention: Evaluating the Role of Vaccines, an Update.”

Glenn S. Tillotson, Ph.D., FRSM, FCCP
Dr. Tillotson, Ph.D., FRSM, FCCP has 30+ years pharmaceutical experience in early pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin and other antibacterials. Glenn has held several key committee positions at the American College of Chest Physicians; he is on the Scientific Steering Committee for the GTCBio. Annual Summit on Anti-infective Partnering. Currently Dr. Tillotson has published >140 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine and F1000.
Presentation Topic:  “Pitfalls and Pinnacles of Developing
Antibiotics for Clostridium difficile.

Abhishek Deshpande, M.D., Ph.D
Abhishek Deshpande, M.D., Ph.D. is an Assistant Professor of Medicine at Cleveland Clinic Lerner College of Medicine and Associate Staff in the Department of Medicine and the Department of Infectious Diseases, at Cleveland Clinic. His research interests include evidence synthesis, comparative effectiveness, clinical practice guideline development and infectious diseases epidemiology. His research focuses on prevention of healthcare-associated infections with an emphasis on Clostridium difficile infection (CDI). His methods include large observational studies, evidence synthesis including meta-analyses, outcomes research and clinical trials. The overall goal of his research is to help reduce the burden and prevent hospital-acquired infections. Dr. Deshpande earned his medical degree from Manipal University, India and his PhD in biomedical sciences from the Kent State University/Cleveland Clinic Collaborative Program. He completed his postdoctoral fellowships from Cleveland Clinic and Case Western Reserve University.
Presentation Topic:  ” UV-C for C. difficile Disinfection – Implementation and Other Issues.”

C. diff. Survivors
Mrs. Kathy Bischoff, and Mrs. Dayle Skelly and
Dr. Sumita Chowdury,MD  –  C. diff. Survivors — join us to share their personal C. difficile infection journey; The signs, symptoms, treatments, with the physical, mental, and psycho-social changes endured from this life-threatening infection and how each recurrent
C. difficile infection (rCDI) impacted their lives.
Presentation Topic:   “A C. diff. Survivor’s Journey.”

Cliff-McDonaldClifford McDonald, MD
Dr. McDonald, MD graduated from Northwestern University Medical School. He completed a medical microbiology fellowship at Duke University and is a former member of CDC’s Epidemic Intelligence Service. Dr. McDonald is currently the Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC. He has first authored or co-authored over 100 peer reviewed publications on subjects related to healthcare and infectious disease epidemiology.
Presentation Topic:  “Clostridium difficile Updates From the Centers for Disease Control and Prevention (CDC) .”

Mary Beth Dorr, PhD
Dr. Dorr is the product development lead for ZINPLAVA (bezlotoxumab), a monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. Mary Beth has a pharmacy degree from the University of the Sciences’ Philadelphia College of Pharmacy and completed a clinical pharmacy residency at the Veteran’s Administration Hospital in Philadelphia. She received a PhD in pharmaceutics with an emphasis on pharmacokinetics and drug metabolism at the University of North Carolina Chapel Hill. Mary Beth joined the pharmaceutical industry in 1988, and has held a variety of positions related to the design and implementation of Phase 1 to 4 clinical trials, primarily for anti-infective products. Mary Beth has wide-ranging drug-development experience at several pharmaceutical companies, including Parke-Davis/Warner Lambert, Rhone-Poulenc Rorer/Aventis, Vicuron, and Wyeth/Pfizer, where she worked in pharmacokinetics/drug metabolism, clinical research, project and alliance management, and medical affairs. Mary Beth joined Merck in 2011 to direct the C. difficile monoclonal antibody clinical development program and led the clinical team through product registration and launch. In addition to her role as the product development team lead, she is responsible for the bezlotoxumab publication strategy and is the clinical director for the pediatric development program for bezlotoxumab.
Presentation Topic:  “Bezlotoxumab Subgroup Analyses:  Patients at High Risk for CDI Recurrence.”

Stephen Marcella, MD
Dr. Marcella, MD is a clinician trained in internal medicine and pediatrics.  After serving in the National Health Service for 4 years and then as a faculty member of a primary care residency, he became interested in clinical epidemiology. Having obtained an MPH from Rutgers in NJ, he spent the next 15 years doing epidemiology research, teaching medical and graduate students, supervising medicine residents, and seeing patients in a federally qualified health care clinic associated with the Robert Wood Johnson Medical School. His research interests have focused largely on prevention and screening and he directed a large NIH-funded study of PSA testing and prostate cancer mortality in New Jersey. He continues to teach at the Rutgers School of Health as an adjunct professor.  For the last four years, Steve has been working as a director in outcomes research at Merck. In the last two years, he has been working on quantifying the burden of illness from Clostridium difficile infection (CDI) and recurrent CDI as well as the health economic data behind Merck’s new product that reduces the recurrence of CDI. This work incorporates elements of health economics, epidemiology, and real world evidence.
Presentation Topic:  ” Early Real-World Evidence of bezlotoxumab Effectiveness As Used In U.S,  Infusion Centers.”

Steven E. Cagas, PhD
Dr. Cagas is with Medical and Scientific Affairs at Roche. He joined Roche 2012 and has worked in several capacities. He has worked directly with customers as part of Global Customer Support by handling complaints as well as assisting customers on site and as part of the Operations Investigation Unit to perform quality investigations related to all kits and components manufactured at Roche Molecular. Steven has been with Medical and Scientific Affairs for over 2 years and is currently the Subject Matter Expert for Microbiology and Donor Screening. Steven has a bachelor’s degree in Biotechnology from Rutgers University and a PhD. in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey.
Presentation Topic: “Antibiotic Stewardship Supported By Diagnostics.”

Richard Vickers, PhD
Dr. Vickers is Chief Scientific Officer, Antimicrobial and Program Lead for CDI, Summit Therapeutics. He joined Summit in 2003 and during his time has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs. This includes leading the discovery and development of ridinilazole, the investigational antibiotic for the treatment of a C. difficile infection. Prior to joining Summit, Dr Vickers undertook postdoctoral research studies with Professor Stephen Davies at the University of Oxford and held a Stipendiary Lectureship in organic chemistry at St. Catherine’s College in Oxford. Dr Vickers received a Ph.D. in organic chemistry from the University of Reading and a B.Sc. in chemistry from King’s College London.
Presentation Topic:  “Ridinilazole for a C. difficile Infection: Update and Progress Towards Phase 3.”

khanna_sahil_13ap-2

Sahil Khanna, MD, MBBS
Dr. Khanna, MD is an Assistant Professor of Medicine in the Division of Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN.  His completed Medical School at the All India Institute of Medical Sciences, New Delhi; followed by Post Doctoral Research at University of California, San Diego, CA; residency in Internal Medicine and Fellowship in Gastroenterology and Hepatology at Mayo Clinic, Rochester, MN before joining the Faculty.  Dr. Khanna has completed Masters in Clinical and Translational Sciences during his fellowship. His research and clinical interests include Epidemiology, Outcomes and Emerging Therapeutics for Clostridium difficile infection, an arena in which he has had numerous publications and presentations.  He is directing the C. difficile Clinic, Fecal Microbiota Transplantation program and C. difficile related Clinical Trials at the May Clinic, Rochester, MN.
Presentation Topic:   “Fecal Transplant for C. difficile: Clinical Experience and Trials!”

gerdingphotoDale Gerding, MD, FACP, FIDSA
Dr. Gerding, MD, FACP, FIDSA, Conference Chair, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital. Prior to his present position Dr. Gerding was Chief of Medicine at VA Chicago, Lakeside Division, and Professor of Medicine at Northwestern University Feinberg School of Medicine. He is an infectious diseases specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America (SHEA) and past chair the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America (IDSA) and past Chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA.
Presentation Topic:  “Update On Newer Agents For Clostridium difficile Infections.”

Joseph Sliman, MD,MPH
Dr. Sliman, MD, MPH, is Chief Medical Officer and joined Synthetic Biologics in January 2013 as the Senior Vice President, Clinical & Regulatory Affairs. In this position, Dr. Sliman will be responsible for the design and implementation of all aspects of clinical development, including clinical trials, and will lead the Company’s regulatory initiatives. During his service in the United States Navy, Dr. Sliman led the U. S. Pacific Fleet disease surveillance programs, including influenza surveillance, preparedness, and prevention, as well as communicable disease and injury surveillance and prevention and health policy development. Dr. Sliman earned an M.D. from the Uniformed Services University, a Master’s Degree in Public Health from the Johns Hopkins University School of Public Health, and a B.S. in Molecular and Cell Biology, with Honors in Biology, from Pennsylvania State University
Presentation Topic:   “An Update on Ribaxamase for the Prevention Of a
Clostridium difficile Infection.”

Stuart B. Johnson, MD,FIDSA, DTM&H
Dr. Johnson, MD,FIDSA, DTM&H, Professor, Department of Medicine, Stritch School of Medicine, Loyola University, Chicago, IL. Dr. Stuart Johnson, MD is a Professor of Medicine at Loyola University Stritch School of Medicine at Loyola University Medical Center and a Researcher at the Hines VA Hospital, Chicago, Illinois. His main research interest and focus has involved the epidemiology pathogenesis, and treatment of Clostridium difficile infection. He is actively studying variant strains of C. difficile and the role of the various toxins in the pathogenesis of C. difficile disease. His clinical experience in the treatment of patients with recurrent CDI has translated into studies helping to define optimal management of these infections, including the utility and pitfalls of alternative treatment agents. He is currently the Principal Investigator of a multi-center study with the VA Healthcare system designed to define optimal management of early
recurrences of CDI.
Presentation Topic:  “Updated IDSA/SHEA Guidelines For the Diagnosis and Treatment of Clostridium difficile Infections.”

Norman B. Javitt, MD, PhD
Dr. Javitt, MD is a research doctor in New York, New York. He received his medical degree from Duke University School of Medicine and has been in practice for more than 20 years. Education and Medical Training: Mount Sinai School of Medicine ,Residency , Internal Medicine,Mount Sinai School of Medicine Residency , Internal Medicine, Mount Sinai School of Medicine ,Internship , Transitional Year Duke University School of Medicine Medical School. Elected Member The American Society for
Clinical Investigation, 1969.
Presentation Topic:   “Ursodeoxycholic Acid Bridge”  Therapy for the Prevention and Treatment of Clostridium difficile Infection.”

simonheadshot-001

Simon M. Cutting, PhD
Professor Cutting of Molecular Microbiology at Royal Holloway, University of London is a bacterial geneticist with over 25 years of experience with Bacillus since graduating from Oxford University with a D. Phil in 1986. His D.Phil was on understanding the genetic control of spore formation in Bacillus Clostridium difficile.. His other expertise is in the use of Bacillus spores as probiotics and has a number of contracts and consultancies with European and US companies in the food and feed sectors.
Presentation Topic:  “New Insights To the Causes of Clostridium difficile Infections.”

Erik R. Dubberke, MD, MSPH
Dr. Dubberke, MD, MSPH is an Associate Professor of Medicine at Washington University School of Medicine in St. Louis, where he has been a faculty member in the Division of Infectious Diseases since 2005. He is an Associate Hospital Epidemiologist at Barnes-Jewish Hospital, Medical Director of Infection Control at Missouri Baptist Medical Center, and is the Director of the Section of Transplant Infectious Diseases at Washington University. He attended medical school at University of Illinois at Chicago, and did his medicine and infectious diseases training at Barnes-Jewish Hospital/Washington University.  He received a Master’s of Science in Public Health from St. Louis University.   His main research interests are in the epidemiology, diagnosis, treatment, and prevention of Clostridium difficile infection (CDI). Dr. Dubberke has over 115 publications, and made the Thomson Reuters list of Highly Cited Researchers in 2015 and 2016. He was the lead author for the CDI component of the Society for Healthcare Epidemiology of America (SHEA) Compendium to Prevent Healthcare Associated Infections, and is on the panel updating the SHEA/IDSA CDI clinical guidelines. He has also represented SHEA as a Key Informant for the AHRQ
Evidence-based Practice Center C. difficile review and at the Department of Health and Human Services Road Map to Eliminate HAI 2013 Action Plan Conference.
Presentation Topic:   “Community-Onset Clostridium difficile Infection.”

Nicola Petrosillo, MD, FESCMID
Dr. Petrosillo, MD,FESCMID earned a degree of Doctor in Medicine and Surgery from the University “La Sapienza” in Rome, Italy in 1977; in the same University, he became specialist in Infectious Diseases (1981) and in Internal Medicine (1985). In 1981, he became hospital infectious diseases registrar and in 1999 Director of an Infectious Diseases Division at the National Institute for Infectious Diseases “Lazzaro Spallanzani” of Rome, Italy.He is fellow of the Pulmonary Vascular Research Institute and leader of the international task-force for pulmonary hypertension associated with HIV, since 2007. He is member of the Professional Affairs SubCommittee on Infectious Diseases and member of the Advisory Board of the Trainee Association of ESCMID. Additionally, he is Professor of Infectious Diseases at the Medical School of Specialization in Hygiene of the Tor Vergata University, Rome, and presently Director, Clinical & Research Department for Infectious Diseases National Institute for Infectious Diseases “Lazzaro Spallanzani”, IRCCS.
Presentation Topic: C.difficile Infection Prevention and Control;  Updates and Controversies”

A. Krishna Rao, MD, MS
Dr. Rao’s clinical, administrative, and research interests include the diagnosis and management of healthcare-associated infections, especially Clostridium difficile infection. His clinical work includes managing the University of Michigan Fecal Microbiota Transplantation (stool transplant) program for recurrent Clostridium difficile infection, a program that he co-founded. His primary research goal is to investigate how biochemical, microbiological, and clinical factors can help clinical decision-making in healthcare-associated infections, and he hopes to ultimately integrate these factors into robust risk-prediction algorithms for use by clinicians. He is currently funded by the NIH and/or CDC to study C. difficile infection, the effect of antibiotics on the gut microbiota, and infections from Gram-negative bacteria, including multi-drug resistant organisms, such as Klebsiella pneumoniae.
Presentation Topic:  “Understanding the Relationship Between Clostridium difficile Infections and the Microbiome; Improving the Signal to Noise Ratio.”

Edmond A. Hooker, MD, DrPH
Dr. Hooker, MD, DrPH, received his B.S. degree from Hampden-Sydney College in Virginia. He earned his M.D. degree from Eastern Virginia Medical School. He then completed his residency training in Emergency Medicine at the University of Louisville. As a full-time faculty member at the University of Louisville from 1991 until 1996, Dr. Hooker served as an Associate Professor and Director of Resident Research. He was very active in brain trauma and stroke research. After leaving the University of Louisville, he worked in Virginia and was on faculty at the University of Virginia. He moved to Cincinnati in 1998. Dr. Hooker works clinically in the emergency department at the University of Cincinnati Hospital, serves as Residency Research Director, and directs the Clinical Research Coordinator’s program. Dr. Hooker serves as a medical advisor to Trinity Guardion. Since 2003, Dr. Hooker has been teaching in the Department of Health Services Administration at Xavier University. In the spring of 2007, Dr. Hooker earned his Doctorate in Public Health from the University of Kentucky. In 2015, he was promoted to Professor. Dr. Hooker continues to be active in emergency medicine and public health research.
Presentation Topic:  ”Re-evaluating Hospital Disinfection: Why Are Hospitals Not Being Disinfected, and What Can We Do to Improve Disinfection?”

Elaine Wang, MD, FIDSA
Dr. Wang, MD, FIDSA graduated from McGill University medical school and received a MSc in Clinical Epidemiology from McMaster University.  She was a practicing pediatric infectious disease specialist at The Hospital for Sick Children reaching a rank Associate Professor in Pediatrics at the University of Toronto, an appointment that she maintains.  She subsequently joined industry to pursue the development of a RSV vaccine. She has worked at Boehringer-Ingelheim, first in clinical development in Virology and Immunology, and then in medical affairs working on their treatment for an orphan disease, idiopathic pulmonary disease.  She has joined Seres Therapeutics to work on their proprietary microbiome-based interventions.
Presentation Topic:  “The Role of the Microbiome in a C. difficile Infection.”

Ciaran P. Kelly, MD
Ciarán P Kelly, MD, is Professor of Medicine at Harvard Medical School and Director of Gastroenterology Fellowship Training at Beth Israel Deaconess Medical Center, in Boston, Massachusetts.  Dr. Kelly earned his medical degree from Trinity College Dublin, Ireland where he was a Foundation Scholar and recipient of numerous academic awards.  Dr Kelly has also received postgraduate clinical and research awards from the Crohn’s and Colitis Foundation of America, the American Gastroenterological Association and the National Institutes of Health.  He is an American Gastroenterology Association Fellow and a Fellow of the American College of Gastroenterology. Dr Kelly has longstanding clinical and research interests in intestinal infection and inflammation.  He has been involved in patient care and research in Clostridium difficile infection for more than 30 years and leads NIH-funded research programs on the immune response to C. difficile infection, C. difficile vaccine development and on novel diagnostic approaches to C difficile infection.  He has also completed studies examining the mechanisms of action of C. difficile toxins and on probiotics in C. difficile infection and in antibiotic-associated diarrhea.
Presentation Topic:  “Ultra-sensitive Toxin Testing for a C. difficile infection: Is This the Way Forward?”

Mark Wilcox, MD, FRCPath
Dr. Wilcox, M.D., FRCPath, Conference Chair, serves as a Consultant Microbiologist, Head & Professor of Medical and Academic Lead of Pathology/Clinical Director of Pathology, at the Leeds Teaching Hospitals (LTHT). Dr. Wilcox is a Professor of Medical Microbiology at the University of Leeds at their Institute of Biomedical and Clinical Sciences and is the lead on Clostridium difficile for Public Health England in the UK. Dr. Wilcox serves as the Principal/UK Investigator for several clinical trials of new anti-infective drugs and has provided clinical advice as part of the FDA/EMA submissions for the approval of several novel antimicrobial agents. He was the Director of Infection Prevention, Infection Control Doctor and Clinical Director of Pathology at LTHT. He serves as Assistant Editor of the Journal of Antimicrobial Chemotherapy and Member of Council of the British Society of Antimicrobial Chemotherapy. Prof. Wilcox serves as a Member of the Department of Health’s Antimicrobial Resistance and Healthcare Associated Infection (ARHAI) Committee and an Advisor to the UK Healthcare Commission, the Medicines and Healthcare products Regulatory Agency, the EPIC project on infection control issues, the Health Technology Assessment (HTA) program on Healthcare Associated Infection and the European Center for Disease Control. Dr. Wilcox serves as a Member of UK, European and US working groups on Clostridium difficile infection.
Presentation Topic:  “Post-C.difficile Irritable Bowel Syndrome.”

Dale Gerding, MD, FACP, FIDSA  and
Stuart B. Johnson, MD,FIDSA, DTM&H
Both Doctor Gerding, Conference Chair,  and
Doctor Johnson will present the latest data and discuss the topic of Antibiotics, the recommended treatments for a CDI and Recurrent – CDI’s with the medications available.

# # # # # # # # # #

 

MEDIA IS WELCOME

November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia PA

Please contact the C Diff Foundation office:  info@cdifffoundation.org or (919)-201-1512

Qualifications and guidelines
Registration is complimentary for professional journalists attending the conference
to provide editorial coverage and who meet the eligibility criteria.

Conference Photography Provided by : Tony DelMonaco

AudioVisual:   PSAV Philadelphia

 

Follow us on Twitter

#Cdiff 2018

@cdiffFoundation